Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has appointed a new chief scientific officer. 9 April 2024
US biotech bluebird bio revealed that it had made mistakes in previous financial statements in a filing with the US Securities and Exchange Commission. 27 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.